Health Catalyst, Inc. (NASDAQ:HCAT) Given Average Rating of “Hold” by Analysts

Health Catalyst, Inc. (NASDAQ:HCAT) has been given an average rating of “Hold” by the thirteen research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $2.7955.

A number of research firms have recently commented on HCAT. Weiss Ratings restated a “sell (e+)” rating on shares of Health Catalyst in a report on Monday, December 29th. Canaccord Genuity Group dropped their target price on shares of Health Catalyst from $5.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, March 13th. Raymond James Financial set a $3.00 price target on shares of Health Catalyst in a report on Friday, March 13th. Cantor Fitzgerald reduced their price target on shares of Health Catalyst from $4.00 to $3.00 and set a “neutral” rating on the stock in a research report on Friday, March 13th. Finally, Stifel Nicolaus decreased their price objective on shares of Health Catalyst from $3.75 to $2.00 and set a “hold” rating for the company in a research note on Friday, March 13th.

Institutional Trading of Health Catalyst

Institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. increased its holdings in Health Catalyst by 6.5% in the 4th quarter. Invesco Ltd. now owns 118,591 shares of the company’s stock valued at $283,000 after purchasing an additional 7,186 shares in the last quarter. Strong Retirement Solutions LLC acquired a new position in shares of Health Catalyst during the fourth quarter worth about $89,000. nVerses Capital LLC acquired a new position in shares of Health Catalyst during the fourth quarter worth about $25,000. Quadrature Capital Ltd purchased a new stake in shares of Health Catalyst in the fourth quarter worth about $64,000. Finally, Bridgeway Capital Management LLC boosted its position in shares of Health Catalyst by 36.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 129,600 shares of the company’s stock worth $310,000 after buying an additional 34,600 shares during the period. 85.00% of the stock is owned by hedge funds and other institutional investors.

Health Catalyst Trading Up 4.7%

HCAT stock opened at $1.22 on Friday. The company has a market cap of $89.41 million, a price-to-earnings ratio of -0.48 and a beta of 1.76. The company has a quick ratio of 1.89, a current ratio of 1.89 and a debt-to-equity ratio of 0.62. The business has a fifty day simple moving average of $1.95 and a 200-day simple moving average of $2.50. Health Catalyst has a 52 week low of $1.04 and a 52 week high of $5.06.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Thursday, March 12th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.02). Health Catalyst had a negative net margin of 57.20% and a negative return on equity of 4.30%. The firm had revenue of $74.68 million during the quarter, compared to analyst estimates of $73.99 million. On average, equities research analysts expect that Health Catalyst will post -0.33 EPS for the current year.

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.